May 3, 2021, 3:42 PM
Organon & Co., a planned Merck & Co. spinoff focused on women’s health, is looking at business development opportunities that can strengthen its offerings in the space, Chief Executive Officer Kevin Ali said in an interview Monday.
The company plans to use its cash flow and any available balance sheet liquidity for bolt-on acquisitions and in-licensing deals, Ali said. Organon, which is slated to carry about $9.5 billion in debt upon being spun off, doesn’t plan to borrow to finance near-term deals.
Ali’s remarks came before the start of Organon’s investor day on Monday, when the company is seeking…